Peter Radovich
2023
In 2023, Peter Radovich earned a total compensation of $2.4M as President and Chief Operating Officer at Mirum Pharmaceuticals, a 52% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $363,600 |
|---|---|
| Option Awards | $977,107 |
| Salary | $505,000 |
| Stock Awards | $508,577 |
| Other | $13,200 |
| Total | $2,367,484 |
Radovich received $977.1K in option awards, accounting for 41% of the total pay in 2023.
Radovich also received $363.6K in non-equity incentive plan, $505K in salary, $508.6K in stock awards and $13.2K in other compensation.
Rankings
In 2023, Peter Radovich's compensation ranked 422nd out of 2,918 executives tracked by ExecPay. In other words, Radovich earned more than 85.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 422 out of 2,918 | 86th |
Division Manufacturing | 241 out of 1,608 | 85th |
Major group Chemicals And Allied Products | 171 out of 901 | 81st |
Industry group Drugs | 168 out of 864 | 81st |
Industry Pharmaceutical Preparations | 106 out of 622 | 83rd |
Source: SEC filing on April 23, 2024.
Radovich's colleagues
We found two more compensation records of executives who worked with Peter Radovich at Mirum Pharmaceuticals in 2023.
News
Mirum Pharmaceuticals CEO Christopher Peetz's 2023 pay jumps 47% to $6.5M
April 23, 2024
Mirum Pharmaceuticals CEO Christopher Peetz's 2022 pay rises 7% to $4.4M
May 1, 2023
Mirum Pharmaceuticals CEO Christopher Peetz's 2021 pay jumps 38% to $4.1M
April 22, 2022
Mirum Pharmaceuticals CEO Christopher Peetz's 2020 pay falls 52% to $3M
April 14, 2021